- likes
- 117
- comments
- 5
Post
For people living with psoriatic arthritis (PsA) and obesity, meaningful progress isn’t defined by a single measure. Beyond disease activity, it can also be reflected in fatigue, physical function and other outcomes that matter to daily life. New 52-week exploratory analyses from the Phase 3b TOGETHER-PsA study showed improved and durable efficacy with two Lilly medicines used together to treat PsA and obesity. The results spanned PsA disease activity, patient-reported and metabolic outcomes. Explore the results presented at #ACR2026 and published in Arthritis & Rheumatology: https://lnkd.in/ecvMi6V7